PREMIO Levagen (Levagen®+)
Levagen® palmitoyl ethanolamide is an endocannabinoid (endogenous, i.e. it is not addictive and has no side effects). The patented LipiSperse® dispersion technology ensures that this formulation is highly bioavailable. Winning awards in prestigious competitions supported by pharmacokinetic and clinical studies published in highly authoritative scientific journals.
Usage instruction
The “gold standard” of use is 8 weeks in a row. The most effective way of use: 2 capsules a day (with fattier food). For pain, the recommended scheme is as follows: 2 capsules when the pain starts and the third capsule after two hours if the pain lasts. A dose of 4 capsules (1200 mg) per day has also been used for pain (used for at least 6 months). One original contains 30 capsules. Read below for which problems it is reasonable to use.
Based on scientific and clinical studies, this product is suitable for the following problems:
- chronic pain (including menstrual pain)
- osteoarthritis problems (stiff joints and mobility problems)
- problems with falling asleep and sleep depth
- inflammations and upper respiratory tract infections
- neurological disorders (including depression and anxiety disorders)
- increased pressure in the eyes (for example, in diabetes and glaucoma)
- constant overeating
- excessive strain on muscles from more intense exercise or physical work
LipiSperse® is a trademark of Pharmako Biotechnologies Pty. Ltd., that is registered in Australia and other countries.
Levagen®+ is a registered trademark owned by Gencor Pacific Ltd.
Levagen+ and acute menstrual pain: Effect of Levagen+ (PEA) compared to a placebo on acute menstrual pain in an adult population – a double-blind, randomised, placebo controlled, cross-over clinical trial (manuscript in preparation, Amanda Rao et al., 2024)
Levagen+ and migraine pain: Effectiveness of Palmitoylethanolamide (Levagen+) Compared to a Placebo for Reducing Pain, Duration, and Medication Use during Migraines in Otherwise Healthy Participants—A Double-Blind Randomised Controlled Study. Pharmaceuticals, 17, 145, Briskey et al., 2024.
PK study - Levagen®+: Increased absorption of Palmitoylethanolamide using a novel dispersion technology system (LipiSperse®). Nutriceuticals Food Sci, Briskey et al., 2020.
Clinical Trial – Exercise study Levagen®+: The effect of orally dosed Levagen®+ (palmitoylethanolamide) on exercise recovery in healthy males. Nutrients, Mallard et al., 2020.
Clinical Trial – Join pain Levagen®+: The effect of a dispersible palmitoylethanolamide Levagen®+ compared to a placebo for reducing joint pain in an adult population. Inflammopharmacology, Steels et al., 2019.
Sleep study - Levagen®+: Palmitoylethanolamide for sleep disturbance. A double-blind, randomised, placebo-controlled interventional study, Sleep Sci Pract, Rao et al, 2021.
Joint/Knee Pain Study - Levagen®+: A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Steels et al., 2019.
Lifetime Management - Levagen®+ : Palmitoylethanolamide: A natural compound for health management. Int J Mol Sci, Clayton et al., 2021.
Covid Study - Levagen®+ : Effects of palmitoylethanolamide on proinflammatory markers in adults recently diagnosed with COVID-19. Current Developments in Nutrition, Fessler et al., 2022.
A systematic review and preliminary metaanalysis of preclinical and clinical evidence. Therapeutic effect of palmitoylethanolamide in cognitive decline: A systematic review and preliminary meta-analysis of preclinical and clinical evidence, Front Psychiatry, Colizzi et al.,2022.
Treatment of Chronic Pain and PEA: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. Nutrients, Lang-Illievich et al., 2023.
| Netto amount | 30 capsules, a daily dose of 2 capsules contains 600mg Levagen®+ (90% palmitoylethanolamide) |
|---|---|
| Ingredients | Levagen®+ palmitoylethanolamide (PEA), dispersion technology LipiSperse®, anti-caking agents magnesium stearate and silicon dioxide, capsule shell emulsifier hydroxypropyl methylcellulose (E464) |
| Warnings | Do not exceed the daily amount. Keep out of reach of children. Store at room temperature in the original packaging away from moisture and light. Do not use as a substitute for a varied diet. It is important to eat a varied and balanced diet and to lead a healthy lifestyle. Medication users, pregnant women and breastfeeding mothers should consult a doctor. |
| Usage | The "gold standard" of use is 8 weeks in a row. The most effective way of use: 2 capsules a day (with fattier food). For pain, the recommended scheme is as follows: 2 capsules when the pain starts and the third capsule after two hours if the pain lasts. A dose of 4 capsules (1200 mg) per day has also been used for pain (used for at least 6 months). One original contains 30 capsules. Read above for which problems it is reasonable to use. |
| Producer/Distributor | Encapsulator/packager: BioPAK Nutraceuticals, Slovenia |
Related products
